This study compares two treatments for low-grade glioma (a common type of brain cancer) in children and young adults. One treatment uses the drug selumetinib, which blocks tumor growth, while the other combines selumetinib with vinblastine, which stops cancer cells from dividing. Researchers want to know if adding vinblastine helps more than using selumetinib alone.

• The study lasts up to 27 treatment cycles (each cycle is 28 days) and involves regular MRIs and blood tests.
• Participants must be 2 to 25 years old, have been treated before, and can swallow capsules.
• Potential risks include typical drug side effects and the need for frequent visits for tests and check-ups.

Those interested must have had prior treatment, be able to handle the medications, and meet specific health requirements. If you or your child meet these criteria and want to help researchers understand better treatments for this cancer, consider joining this study.